Mucormycosis represents the third most common invasive fungal infection in children, and recent studies have suggested a rising incidence. Its case fatality rate is high, especially for neonates. Clinical presentation is influenced by underlying risk factors; associations with immunosuppression, neutropenia, diabetes, and prematurity have been described. It has been implicated in several hospital outbreaks. Diagnosis requires a high index of suspicion and evaluation with histopathology, culture, and, increasingly, molecular identification. Surgical debridement and antifungal therapies are the cornerstone for combatting invasive mucormycosis. However, the severity and relative rarity of this disease make comparative clinical trials for evaluating antifungal therapies in children difficult to conduct. Hence, therapeutic decisions are derived mainly from retrospective case series, in vitro data, and animal models. In this review, we summarize the literature on the epidemiology and diagnosis of this invasive fungal infection and provide suggestions on the management of mucormycosis in children.
Mucormycosis affects adults and children and is associated with significant morbidity and death in immunocompromised and immunocompetent hosts. Here, we review the literature regarding mucormycosis in children and use the evidence to provide recommendations for management.
METHODS
We conducted a search of the published literature through the National Library of Medicine (PubMed) using the search terms ("mucormycosis"[medical subject heading (MeSH) terms] or "mucormycosis"[all fields]) or ("zygomycosis" [MeSH Terms] or "zygomycosis"[all fields]) and ("child"[MeSH Terms] or "child*"[all fields]) or "paediatrics" [MeSH Terms] or "pediatric*"[all fields]). To supplement the search strategy, reference lists from all identified studies and key review articles on mucormycosis epidemiology, diagnosis, and treatment were reviewed to identify additional relevant articles that contain pediatric data.
MICROBIOLOGY
Mucormycosis is an infection caused by fungi that belong to the order Mucorales. These ubiquitous fungi inhabit soil and organic debris. They grow rapidly and sporulate quickly and abundantly. Mucormycosis in humans is caused most frequently by species of the Mucoraceae family of the Mucorales order, giving rise to the term mucormycosis, which has replaced the commonly used term zygomycosis. The most commonly encountered species is Rhizopus arrhizus, but other organisms that are identified frequently include Mucor species, Lichtheimia species (previously known as Absidia species), and Cunninghamella species (Table 1) [1, 2] .
EPIDEMIOLOGY
As a group, Mucoraceae represent the third most common cause of invasive fungal infection after Candida and Aspergillus species [3] . An increasing incidence of mucormycosis has been suggested by epidemiologic studies [4] . Many factors can contribute to this increase, including selection pressure from antifungal prophylaxis by agents without mucormycosis activity [1] . Voriconazole use in immunosuppressed patients has been singled out as a significant independent risk factor for mucormycosis (odds ratio, 10.37 [95% confidence interval (CI), 2.76-38.97]; P < .001) [2] . However, there is evidence that mucormycosis rates were increasing before the widespread use of voriconazole, which indicates that other factors, such as increased use of immunosuppressive therapies, also contribute [5] . It is also possible that higher observed rates are related to increased awareness and more aggressive diagnostic evaluation rather than simply a true increase in the number of infections.
RISK FACTORS
Although immune dysfunction is a risk factor for invasive disease, the association with immunodeficiency is less than that seen with invasive aspergillosis. Mucormycosis is not classically associated with any particular form of primary immunodeficiency [6] . Hematologic malignancy is a significant risk factor, as is being a hematopoietic stem cell transplant or solid organ transplant recipient. Solid organ malignancy (without transplant) is not commonly associated with mucormycosis [7] . Diabetes also is a commonly identified risk factor, with 9% to 36% of cases occurring in diabetics [7] [8] [9] .
Iron overload, deferoxamine therapy, intravenous drug use, and renal failure are seen less frequently, particularly in children, but remain well-recognized risk factors. Burns and traumatic wounds are particularly associated with cutaneous mucormycosis and account for a significant proportion of patients with no apparent immunodeficiency [6] . Outbreaks of cutaneous infection are also known to occur after natural disasters [10] . Underlying rheumatologic/autoimmune disorders were reported more recently as a risk for infection and poor outcome [7] . Prematurity is a major risk factor for disease (especially gastrointestinal and cutaneous mucormycosis) in neonates [11] [12] [13] . In some pediatric cases (9.5% in 1 case series), no specific underlying risk factors were identified [14] .
CLINICAL MANIFESTATIONS
The most frequent types are rhinoorbitocerebral, pulmonary, cutaneous, and gastrointestinal infections [6] . Dissemination of disease occurs in 32% to 38% of pediatric cases and more than half of neonatal cases [11, 12, 14] . The distribution of disease is influenced significantly by underlying risk factors. Rhinoorbitocerebral sinus disease is the most common manifestation in patients with diabetes (22 [66%] of 33 in 1 study [9] ) and is commonly associated with diabetic ketoacidosis. It presents with progressive sinusitis with fever, headache, and nasal discharge and eventual spread of tissue necrosis (manifest as a black eschar) involving the nasal mucosa, palate, overlying facial skin, orbit, and brain. Pulmonary disease predominates in patients with malignancy (92 [60%] of 154 in 1 study [9] ). Children with pulmonary mucormycosis typically present with a progressive pneumonia associated with lung necrosis, hemoptysis, and spread to contiguous structures. Cutaneous infection, which makes up 19% of all cases [9] and 27% of cases in children [11, 12] , presents with nonspecific signs of inflammation that might or might not progress to form a necrotic eschar [6] . In the neonatal period, gastrointestinal and cutaneous diseases are seen more frequently than in older age groups (54% and 36% of neonatal cases, respectively) [11] . Neonatal gastrointestinal infection can manifest as necrotizing enterocolitis and has been associated with late diagnosis and high case fatality rates (CFRs) (78%).
DIAGNOSIS
Diagnosis of mucormycosis is made most frequently on the basis of histopathologic characteristics (broad, hyaline, hyposeptated hyphae, in concert with angioinvasion and tissue necrosis) in the appropriate clinical setting. Culture is poorly sensitive because of the fragility of Mucorales hyphae, which frequently are damaged during sample collection. As a result, only approximately one-third of all microscopically positive specimens result in a positive culture [15] . Specificity is also an issue, because isolation from nonsterile sites is sometimes indicative of contamination rather than disease. Culture of a clinically relevant isolate enables identification and susceptibility testing of the pathogen [16] .
Histopathology and culture still form the basis of diagnosis in most cases, although molecular techniques are being used increasingly to complement traditional methods [17] . Molecular testing improves the accuracy of species identification compared to phenotypic identification of culture isolates [15] . Nucleic acid amplification techniques that target the ribosomal DNA gene targets 18S, 28S, and Internal Transcribed Spacer (ITS) region are all used. The sensitivity and specificity of molecular diagnosis performed directly on fresh or frozen tissue depend on the DNA-extraction method used [15] . Fresh material is preferred over paraffin-embedded tissue, because formalin damages DNA [16] .
TREATMENT OF MUCORMYCOSIS
Surgical debridement and antifungal therapy are the mainstays of management of invasive mucormycosis. They both are associated with improved outcomes in adults and children, and in most cases, a combined approach is indicated [9, 16] .
Pooled pediatric data have shown that children who received antifungal therapy and underwent surgery had a CFR of 18.5%, compared with 60% for those who received antifungal therapy Other 55 (9) alone [14] . A review of 255 cases of pulmonary mucormycosis (including cases that involved dissemination) found that surgical intervention reduced the CFR rate to 11% compared with 68% in those treated with medical therapy only (P = .0004) [18] . A survival advantage is also conferred on those who undergo surgery for disease localized to the lung [19] [20] [21] . Dissemination frequently occurs before respiratory failure develops, and surgery serves to reduce the risk of fungal sepsis and protect respiratory function. Patients who have a good early response to antifungal therapy can be managed conservatively, but in the absence of clinical improvement and if operative risk is deemed acceptable, consideration should be given to wedge resection, lobectomy, or pneumonectomy, depending on the extent of disease [20] . Extensive surgical debridement is thought to be important in treating cutaneous mucormycosis, and repeated surgery is often required to ensure adequate debridement and address disease progression [22, 23] . Similarly, aggressive resection is imperative in the management of rhinocerebral mucormycosis, which is associated with a high CFR in immunocompromised people regardless of intervention [18, 24] . Surgery has not been shown conclusively to improve outcomes for neonates with gastrointestinal mucormycosis, which is frequently fatal despite aggressive management [11] . When possible, a combined surgical and medical approach is recommended nonetheless, because it is likely to offer the best chance of survival [25, 26] .
Comparative clinical trials that evaluate antifungal agents against mucormycosis are difficult to conduct because of the rarity of the illness and the challenges associated with enrolling sufficient numbers of subjects to demonstrate a significant difference in treatment strategies. As a result, treatment recommendations are based largely on retrospective case series, in vitro data, and animal models [16] .
Amphotericin B (AmB) has activity against Mucorales in vitro [27, 28] . Both conventional AmB (cAmB) and AmB lipid complex (ABLC) have been associated with improved survival rates (324 [61%] of 532 and 80 [69%] of 116, respectively) compared with 18% survival (59 of 333) among those not treated with antifungal therapy [9] . Pediatric analysis of ABLC (median dose, 4.92 mg/kg per day) in the treatment of invasive fungal infections included a very small number (n = 4) of children with mucormycosis [29] . ABLC administered at 5 mg/kg per day is safe and tolerated by children; however, it is not recommended for those with central nervous system (CNS) involvement [16] .
Liposomal amphotericin (LAmB) has better CNS penetration than cAmB or ABLC [30] and is associated with fewer adverse effects than is cAmB [31, 32] . Thus, LAmB has evolved as the cornerstone of primary therapy for mucormycosis and has been linked to improved outcomes in multivariate analysis when used (at a dose of 3 mg/kg per day) to treat mucormycosis in patients with a hematologic malignancy [33] . Recommendations for dosing LAmB vary considerably, ranging from 3 to 10 mg/kg per day [8, 16] . Consensus expert opinions suggest administering at [16, 32] . Dosages of LAmB as high as 15 mg/kg per day are tolerated, but doses higher than 10 mg/kg per day do not result in an increased plasma concentration [34] . A pilot clinical trial that evaluated initial high-dose (10 mg/kg per day) LAmB for mucormycosis (with surgery in two-thirds of cases) found a 45% response rate at week 12, although renal toxicity frequently occurred (40%) [35] .
Most commercially available oral antifungal agents have no in vitro or in vivo activity against mucormycosis [27] . Posaconazole is an exception; in vitro [36] and in vivo data support its use in salvage therapy and in step-down therapy of invasive mucormycosis [16, 37] . Most available clinical data are in the form of case reports, although 2 adult case series reported complete or partial response in 60% (n = 91) and 79% (n = 24) of patients, respectively [38, 39] . Most patients had been treated already with LAmB and surgical debridement. Posaconazole was given at a dose of 800 mg/day in divided doses, and no adjustment for weight was made [38] . More recently, a retrospective analysis of 96 published case reports of oral posaconazole treatment found a complete or partial response in 64.6% and 7.3% of patients, respectively [37] . Selection biases in such salvage studies make interpretation difficult. In vitro and animal studies have indicated variable susceptibility to different Mucorales strains and overall superior performance of AmB [36, 40] . One murine model found poor in vivo activity of posaconazole against Mucor circinelloides [41] , and another study raised concerns about the effectiveness of posaconazole against R arrhizus (previously known as Rhizopus oryzae) [41] . Newer formulations of posaconazole have become available. The delayed-release tablet has improved bioavailability over that of the oral suspension and enables once-daily dosing [41, 42] . Intravenous posaconazole is available also. These medications have not been studied yet for mucormycosis, but they have been applied successfully in neutropenic murine models [43] .
Clinical data for the use of posaconazole salvage therapy in children are limited and insufficient to determine confident dosing recommendations [44] , although European clinical guidelines suggest 18 to 24 mg/kg per day of oral posaconazole suspension, given in 4 divided doses, for patients younger than 13 years who weigh less than 34 kg [16] . These recommendations are based on very limited data, and further pharmacokinetic studies are underway to evaluate optimal dosing for different pediatric age groups. Routine therapeutic drug monitoring is also recommended to ensure adequate concentrations [45] . Posaconazole penetrates the cerebrospinal fluid (CSF) relatively poorly, but CSF concentration is probably improved in the setting of meningeal inflammation [46] .
One pharmacokinetic study analyzed posaconazole plasma concentrations in 12 children, 11 of whom received a standard adult dose of 800 mg/day irrespective of their weight (range, 24-76 kg). One 8-year-old child (weight, 39.4 kg) received 400 mg/ day. The average posaconazole plasma concentrations were highly variable (range, 85-2891 ng/ml), but no association with age, body weight, or body surface area could be found, and correlation of plasma concentrations with treatment outcomes has not been established. The mean for the 12 children was comparable to that of a cohort of 194 adults treated with 800 mg/day of posaconazole (children, 776 ng/ml; adults, 817 ng/ml) [47] . Treatment success using posaconazole salvage therapy in 4 of 7 children with invasive mucormycosis has been described, and only mild adverse effects were observed [48] . In that study, which evaluated a total of 15 children treated with posaconazole for invasive fungal infection, the median total daily dose was 21 mg/kg per day (95% CI, 17-25 mg/kg per day; range, 4.8-33.3 mg/kg per day). One 10-year-old received a daily dose of 1200 mg/day, which is significantly higher than the usual adult dose. Plasma levels were not measured routinely. Only mild adverse effects, including fever, abdominal symptoms, headache, and skin rashes, were observed, and none of them necessitated the cessation of posaconazole [48] .
Isavuconazole is a novel triazole with a wide spectrum of activity against yeasts and molds such as Mucorales [49] and Aspergillus [50] species. A multicenter open-label trial recently showed that isavuconazole was safe in adults when used as primary treatment against mucormycosis and had an efficacy similar to that of AmB in a matched case-control analysis [51] . However, external control patients received different formulations of AmB (cAmB, ABLC, LAmB), and the small study size precluded further subanalysis. Increasing evidence supports its use as a new treatment option for invasive mold diseases, and its predictable pharmacokinetics and high bioavailability make it an attractive option [52] . Although CSF concentration is low, isavuconazole is thought to achieve adequate brain penetration for treatment of CNS infections [53] . Current recommendations suggest its use for deescalation, in refractory cases, or for patients intolerant to AmB for the treatment of mucormycosis in adults [54, 55] . There is a lack of pediatric data, and no specific dosing recommendations for treating children currently exist.
The total duration of antifungal therapy required is not known and cannot be clearly established from the available literature because of multiple confounding variables in published retrospective case series. The duration of therapy given typically varies greatly depending on patient characteristics and the extent of diseases caused by the Mucorales infection. In patients with adequate renal function, at least 3 weeks of parenteral AmB followed by deescalation to oral posaconazole has been suggested [56] . Early reports indicate that a median length of amphotericin-based therapy of 21 days was used for survivors. Nonsurvivors from all patient groups had a shorter median length of treatment, but that might simply represent more aggressive disease resulting in premature death rather than an inappropriately short duration of therapy [9] . One series of posaconazole-treated patients underwent a median length of treatment of 5 months (range, 7 days to 34 months) [37] . Treatment usually is continued for multiple weeks and is discontinued only once clinical resolution is evident, follow-up culture results are negative, immunologic recovery has occurred, and, when relevant, radiologic resolution on serial imaging is evident [16, 56] .
The high CFR associated with mucormycosis, even with optimal surgical management and antifungal therapy, make combination antifungal therapy an attractive idea. Prospective clinical trials in which combination therapy and monotherapy were compared are lacking [32] . Synergy has been demonstrated in vitro between posaconazole and AmB [57] and posaconazole and caspofungin [58] , although a murine model did not respond better to combination AmB plus posaconazole than to AmB monotherapy [59] . However, in a case series (n = 32) of patients with mainly hematologic diseases, combinations of ABLC and posaconazole resulted in 56% treatment response after 3 months [60] . The reason for the synergistic effect of caspofungin in combination with other agents is not well understood given its lack of activity against Mucorales in vitro, although R oryzae has been shown to express the enzyme 1,3-β-d-glucan synthase, which is inhibited by caspofungin [61] . Encouraging results of ABLC plus caspofungin combination therapy in a diabetic murine model [62] and of LAmB plus micafungin in mice with disseminated mucormycosis [63] prompted a group of clinician researchers to change their practice in the management of a patient with rhinoorbitocerebral mucormycosis. After treating 7 patients with a polyene-caspofungin combination therapy, they retrospectively analyzed their data and reported success 30 days after hospital discharge in 6 (86%) of 7 patients treated with polyene-caspofungin compared with 14 (41%) of 34 managed with polyene monotherapy (P = .040) [64] . Small numbers of patients in the study and a patient cohort limited to those with diabetes make it difficult to adjust for covariates and limit the generalizability of these findings [64] . In contrast, a retrospective analysis of 106 patients with a hematologic malignancy found no differences in mortality rates at 6 weeks between patients receiving monotherapy and those receiving combination treatment as initial therapy for mucormycosis (43% vs 41%, respectively; P = .85) [65] . Hence, the value of combination strategies remains unclear, and additional research is needed in this area to evaluate amphotericin-based treatment with the addition of an echinocandin or triazole antifungal agent.
NOSOCOMIAL MUCORMYCOSIS
The numbers of reports of healthcare-associated mucormycosis are steadily increasing. Reports of outbreaks have included between 2 and 5 cases of suspected or confirmed mucormycosis within a healthcare institution. A summary of 169 published cases (163 of which were laboratory proven) identified immunosuppression (prolonged steroid therapy, solid organ transplant, malignancy, and other immunodepression factors) in 78% of the cases; 22% had diabetes mellitus, 21% were neonates, and only 6% had no comorbidity [66] . The mortality rate was reported at 50% but was higher (64%) in the neonatal population [66] .
Rhizopus species are involved most commonly, although Mucor, Rhizomucor, and Absidia species have been identified also [67] . In each published series, a source of contamination has been hypothesized or proven. Adhesive tapes are implicated frequently [68] . Wooden tongue depressors, ostomy bags, hospital linen, ventilation systems, and construction sites have been identified also as potential or proven havens of the pathogen in the context of different hospital outbreaks [66, [68] [69] [70] .
Whenever 2 or more cases that involve the same organism have been identified within a healthcare institution during a 6-month period, a common source or sources for infection should be considered, and environmental investigations that include formal air sampling and testing should be conducted [67, 71] .
OUTCOME
On the basis of published reports of invasive mucormycosis, the CFR is very high at 47% to 56% and rises to 96% for those with disseminated disease [7] [8] [9] . The CFR might be inflated by reporting bias, given epidemiologic findings that suggest lower CFRs than those reported elsewhere in the literature [4] . Survival without antifungal therapy is rare [9] . The CFR in older children is consistent with those seen in adults, with a trend toward higher rates in neonates (64% CFR in infants <1 month of age; 56% CFR in children aged 1 month to 18 years) [11] . An age of less than 1 year is a significant independent risk factor for death (odds ratio, 3.85 [95% CI, 1.05-7.43]) [12] . Dissemination and past hematopoietic stem cell transplantation were also found to be independent risk factors for mortality [14] . In the absence of dissemination or local extension, cutaneous mucormycosis alone has not been associated with mortality in children [12, 14] . Gastrointestinal disease in neonates, by comparison, is frequently (78%) fatal [11] .
CONCLUSION
When the diagnosis is suspected, invasive mucormycosis requires a high index of suspicion and urgent evaluation of clinical samples. The disease is typically progressive and frequently fatal. Surgical debridement should be considered and is usually necessary to prevent contiguous spread and dissemination. Institution of medical therapy is also an urgent priority, because delays have been associated with significant increases in deaths [72] . Initial medical therapy should constitute an amphotericin preparation, ideally intravenous LAmB dosed at 5 mg/kg per day (10 mg/kg per day in case of CNS involvement). In patients who are stabilized after surgery and commencement of parenteral antifungal therapy, step-down to oral posaconazole can be considered. Posaconazole is also a suitable alternative to AmB (in the absence of CNS involvement) if renal toxicity develops or AmB is not tolerated for other reasons. For cases in which deterioration occurs despite appropriate treatment, evidence for other treatment approaches is very limited. Escalation of treatment could include repeated surgical debridement, an increased dose of LAmB up to 10 mg/kg per day, the addition or switch to posaconazole or isavuconazole, or the addition of an echinocandin, but none of these strategies are proven to be effective. Antifungal therapy should be continued until clinical resolution, and monitoring for recurrence after discontinuation of treatment is important. Hospital-acquired infection should prompt consideration of possible sources of contamination, with a view to the early identification of all potential outbreaks and implementation of appropriate source control. 
